RE002 T Cell Injection for the Treatment of KRAS G12D Mutated Solid Tumors

NCT06546150 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

30

Enrollment

OTHER_GOV

Sponsor class

Conditions

KRAS G12D
T Cell Therapy

Interventions

BIOLOGICAL: RE002 T cell

Sponsor

Henan Cancer Hospital